Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

Blood

Volumn 104, Issue 7, 2004, Pages 1995-1999

  Lo Coco, Francesco ^a   Cimino, Giuseppe ^b   Breccia, Massimo ^b   Noguera, Nélida I ^b   Diverio, Daniela ^b   Finolezzi, Erica ^b   Pogliani, Enrico M ^b   Di Bona, Eros ^b   Micalizzi, Concetta ^b   Kropp, Mariagrazia ^b   Venditti, Adriano ^b   Tafuri, Agostino ^b   Mandelli, Franco ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CD33 ANTIGEN; COMPLEMENTARY DNA; CYTARABINE; DIPHENHYDRAMINE; GEMTUZUMAB OZOGAMICIN; HUMAN MONOCLONAL ANTIBODY; IDARUBICIN; MITOXANTRONE; PARACETAMOL; RETINOIC ACID;

ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; LIVER TOXICITY; MALE; NAUSEA; NEUTROPENIA; POLYURIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PYREXIA IDIOPATHICA; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 4644293319     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1550     Document Type: Article

References (21)

1. Tallman MS, Nabhan CH, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759-767.
2. Douer D. New advances in the treatment of acute promyelocytic leukemia. Int J Hematol. 2002;76:179-187.
3. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 2003;17:1454-1463.
4. Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94:2225-2229.
5. Lo Coco F, Breccia M, Diverio D. The importance of molecular monitoring in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:503-520.
6. Appelbaum FR. Antibody-targeted therapy for myeloid leukemia. Semin Hematol. 1999;36:2-8.
7. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8:521-534.
8. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood. 1988;72:314-321.
9. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
10. Sievers EL, Larson RA, Stadtmauer EA, et al, and the Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
11. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003;102:4277-4283.
12. Jurcic JG, De Blasio T, Dumont L, Yao TJ, Scheingerg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal anti-body HuM195 in acute promyeloctic leukemia. Clin Cancer Res. 2000;6:372-380.
13. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002, 99:4222-4224.
14. Petti MC, Pinazzi MB, Diverio D, et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol. 2001;115:63-65.
15. Diverio D, Rossi V, Awisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood. 1998;92:784-788.
16. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer Program. Leukemia. 2003;17:2318-2357.
17. Cheson BD, Bennett JM, Kopecky KJ, et al, and the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649.
18. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and childhood acute promyelocytic leukemia: correlation with morphology and type of PML gene breakpoint: a cooperative Italian study on 196 cases. Br J Haematol. 1998;102:1035-1041.
19. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:369-385.
20. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol. 2000;108:703-709.
21. Lo-Coco F, Romano A, Mengarelli A, et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia. 2003;17:1930-1933